Electrospun Micro- and Nanofibers for Sustained Delivery of Paclitaxel to Treat C6 Glioma in Vitro
The present study aims to develop electrospun PLGA-based micro- and nanofibers as implants for the sustained delivery of anticancer drug to treat C6 glioma in vitro.
PLGA and an anticancer drug—paclitaxel-loaded PLGA micro- and nanofibers were fabricated by electrospinning and the key processing parameters were investigated. The physical and chemical properties of the micro- and nanofibers were characterized by various state-of-the-art techniques, such as scanning electron microscope and field emission scanning electron microscope for morphology, X-ray photoelectron spectroscopy for surface chemistry, gel permeation chromatogram for molecular weight measurements and differential scanning calorimeter for drug physical status. The encapsulation efficiency and in vitro release profile were measured by high performance liquid chromatography. In addition, the cytotoxicity of paclitaxel-loaded PLGA nanofibers was evaluated using 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide MTT) assay on C6 glioma cell lines.
PLGA fibers with diameters of around several tens nanometers to 10 μm were successfully obtained by electrospinning. Ultrafine fibers of around 30 nm were achieved after addition of organic salts to dilute polymer solution. The encapsulation efficiency for paclitaxel-loaded PLGA micro- and nanofibers was more than 90%. DSC results suggest that the drug was in the solid solution state in the polymeric micro- and nanofibers. In vitro release profiles suggest that paclitaxel sustained release was achieved for more than 60 days. Cytotoxicity test results suggest that IC50 value of paclitaxel-loaded PLGA nanofibers (36 μg/ml, calculated based on the amount of paclitaxel) is comparable to the commercial paclitaxel formulation-Taxol®.
Electrospun paclitaxel-loaded biodegradable micro- and nanofibers may be promising for the treatment of brain tumour as alternative drug delivery devices.
Key wordselectrospinning glioma microfibers nanofibers paclitaxel PLGA
This work is supported by the Science and Engineering Research Council, A*STAR and National University of Singapore under the grant number R279-000-208-305. The authors thank Liang Kuang Lim, Lai Yeng Lee and Dr. Yong Hu for helpful discussion and technique support.
- 4.B. Chu, B. S. Hsiao, D. Fang, and C. Brathwaite. Biodegradable and/or bioabsorbable fibrous articles and methods for using the articles for medical applications. US patent 6,689,374 (2004).Google Scholar
- 12.B. Chu, B. S. Hsiao, M. Hadjiargyrou, D. Fang, X. Zong, and K. Kim. Cell delivery system comprising a fibrous matrix and cells. US Patent 6,790,455 (2004).Google Scholar
- 22.S. Fellner, B. Bauer, D. S. Miller, M. Schaffrik, M. Fankhanel, T. Spruh, G. Bernhardt, C. Graeff, L. Farber, H. Gschaidmeier, A. Buschsuer, and G. Fricker. Transport of Paclitaxel (Taxol) across the blood-brain barrier in vitro and in vivo. J. Clin. Invest. 10(9):1309–1317 (2002).Google Scholar
- 23.R. Klecker, C. Jamis-Dow, M. Egorin, K. Erkmen, R. Parker, and J. Collins. Distribution and metabolism of 3H-Taxol in the rat. Proc. Am. Assoc. Cancer Res. 34:380 (1993).Google Scholar
- 24.J. J. Heimans, J. B. Vermorken, J. G. Wolbers, C. M. Eeltink, O. W. M. Meijer, M. J. B. Taphoorn, and J. H. Beijnen. Paclitaxel (Taxol) concentrations in brain tumor tissue. Ann. Onc. 5:951–953 (1994).Google Scholar